Michelle D. Williams

Michelle D. Williams

Auto-generated profile, based on publicly available information

Michelle D. Williams

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in Cell
Verified
Journal Article
Open access
NANishant Agrawal
Nishant Agrawal
RARehan Akbani
Rehan Akbani
BAB. Arman Aksoy
B. Arman Aksoy
AAAdrian Ally
Adrian Ally
HAHarindra Arachchi
Harindra Arachchi
LZLihua Zou
Lihua Zou
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we describe the genomic landscape of 496 PTCs. We observed a low frequency of somatic alterations (relative to other carcinomas) and extended the set of known PTC driver alterations to include EIF1AX, PPM1D, and CHEK2 and diverse gene fusions. These discoveries reduced the fraction of PTC cases with unknown oncogenic driver from 25% to 3.5%. Combined analyses of genomic variants, gene expression, and methylation demonstrated that different driver groups lead to different pathologies with distinct signaling and differentiation characteristics. Similarly, we identified distinct molecular subgroups of BRAF-mutant tumors, and multidimensional analyses highlighted a potential involvement of oncomiRs in less-differentiated subgroups. Our results propose a reclassification of thyroid cancers into molecular subtypes that better reflect their underlying signaling and differentiation properties, which has the potential to improve their pathological classification and better inform the management of the disease.

1 August 2017 in Cancer Cell
Verified
Journal Article
Open access
ARA. Gordon Robertson
A. Gordon Robertson
JSJuliann Shih
Juliann Shih
CYChristina Yau
Christina Yau
EGEwan A. Gibb
Ewan A. Gibb
JOJunna Oba
Junna Oba
EZErik Zmuda
Erik Zmuda
Comprehensive multiplatform analysis of 80 uveal melanomas (UM) identifies four molecularly distinct, clinically relevant subtypes: two associated with poor-prognosis monosomy 3 (M3) and two with better-prognosis disomy 3 (D3). We show that BAP1 loss follows M3 occurrence and correlates with a global DNA methylation state that is distinct from D3-UM. Poor-prognosis M3-UM divide into subsets with divergent genomic aberrations, transcriptional features, and clinical outcomes. We report change-of-function SRSF2 mutations. Within D3-UM, EIF1AX- and SRSF2/SF3B1-mutant tumors have distinct somatic copy number alterations and DNA methylation profiles, providing insight into the biology of these low- versus intermediate-risk clinical mutation subtypes.

1 May 2014 in Oral and Maxillofacial Surgery Clinics of North America
Verified
Journal Article
Closed access
NVNadarajah Vigneswaran
Nadarajah Vigneswaran
MWMichelle D. Williams
Michelle D. Williams

15 March 2016 in Cancer
Verified
Journal Article
Open access
PDF file
CCChandrani Chattopadhyay
Chandrani Chattopadhyay
DKDae Won Kim
Dae Won Kim
DGDan Gombos
Dan Gombos
JOJunna Oba
Junna Oba
YQYong Qin
Yong Qin
SPSapna Patel
Sapna Patel
Melanomas of the choroid, ciliary body, and iris of the eye are collectively known as uveal melanomas. These cancers represent 5% of all melanoma diagnoses in the United States, and their age‐adjusted risk is 5 per 1 million population. These less frequent melanomas are dissimilar to their more common cutaneous melanoma relative, with differing risk factors, primary treatment, anatomic spread, molecular changes, and responses to systemic therapy. Once uveal melanoma becomes metastatic, therapy options are limited and are often extrapolated from cutaneous melanoma therapies despite the routine exclusion of patients with uveal melanoma from clinical trials. Clinical trials directed at uveal melanoma have been completed or are in progress, and data from these well designed investigations will help guide future directions in this orphan disease. Cancer 2016;122:2299–2312. © 2016 American Cancer Society.

1 April 2017 in Thyroid®
Verified
Journal Article
Closed access
BHBryan R. Haugen
Bryan R. Haugen
ASAnna M. Sawka
Anna M. Sawka
EAErik K. Alexander
Erik K. Alexander
KBKeith C. Bible
Keith C. Bible
PCPatrizio Caturegli
Patrizio Caturegli
MWMichelle D. Williams
Michelle D. Williams
American Thyroid Association (ATA) leadership asked the ATA Thyroid Nodules and Differentiated Thyroid Cancer Guidelines Task Force to review, comment on, and make recommendations related to the suggested new classification of encapsulated follicular variant papillary thyroid carcinoma (eFVPTC) without capsular or vascular invasion to noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). The task force consists of members from the 2015 guidelines task force with the recusal of three members who were authors on the paper under review. Four pathologists and one endocrinologist were added for this specific review. The manuscript proposing the new classification and related literature were assessed. It is recommended that the histopathologic nomenclature for eFVPTC without invasion be reclassified as a NIFTP, given the excellent prognosis of this neoplastic variant. This is a weak recommendation based on moderate-quality evidence. It is also noted that prospective studies are needed to validate the observed patient outcomes (and test performance in predicting thyroid cancer outcomes), as well as implications on patients' psychosocial health and economics.

20 April 2010 in Cancer
Verified
Journal Article
Open access
PDF file
MMMauricio A. Moreno
Mauricio A. Moreno
DRDianna B. Roberts
Dianna B. Roberts
MKMichael E. Kupferman
Michael E. Kupferman
FDFranco DeMonte
Franco DeMonte
AEAdel K. El‐Naggar
Adel K. El‐Naggar
EHEhab Y Hanna
Ehab Y Hanna
BACKGROUND: Sinonasal mucosal melanoma is a rare disease associated with a very poor prognosis. Because most of the series extend retrospectively several decades, we sought to determine prognostic factors and outcomes with recent treatment modalities.METHODS: A retrospective chart review of 58 patients treated for sinonasal melanoma at a tertiary cancer center between 1993 and 2004. The patients were retrospectively staged according to the sinonasal American Joint Committee on Cancer (AJCC) staging system. Demographic, clinical and pathological parameters were identified and correlated with outcomes.RESULTS: There were 35 males and 23 females with a median age of 63 years; 56 patients were treated surgically and 33 received radiation therapy. According to Ballantyne's clinical staging system, 88% of the patients presented with stage I (local) disease. Classification by the AJCC staging classified yielded 27% of the patients with T1, 33% with T2, 21% with T3, and 19% with T4. T‐stage and the degree of tumor pigmentation were associated with a worse survival (P = .0096 and P = .018, respectively), while pseudopapillary architecture was associated with a higher locoregional failure (P = .0144). Postoperative radiation therapy improved locoregional control when a total dose greater than 54 Gy was used (P = .0215), but did not affect overall survival.CONCLUSIONS: Tumor stage according to sinonasal AJCC staging system is an effective outcome predictor and should be the staging system of choice. Postoperative radiation therapy improves locoregional control when a higher dose and standard fractionations are used. Histological features such as pigmentation and pseudopapillary architecture are associated with worse outcome. Cancer 2010. © 2010 American Cancer Society.